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Abstract Our understanding of the way antibodies are built in
vivo has provided an approach for engineering synthetic human
antibodies in bacteria. Such antibodies have not only been raised
against foreign antigens, but also against highly conserved
antigens or human self-antigens, and have considerable practical
potential as reagents for research and also as therapeutics. The
approach also has implications for the design of antibody
repertoires and for engineering other proteins with desirable
binding properties. This review takes a personal view.
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1. Introduction
The discipline of the organic chemist is that the determina-
tion of the structure of a natural molecule is not regarded as
complete until the same molecule has been chemically synthe-
sised. It is usually di⁄cult to apply such disciplines in the
biological sciences. However our understanding of the way
antibodies are made in vivo has inspired the creation of an
arti¢cial immune system that has proved capable of making
human antibodies in bacteria [1,2] (Fig. 1).
The antigen binding site is comprised of two associated
domains, the heavy (H) and light (L) chain variable domains,
which together form a L-sheet framework for six antigen bind-
ing loops. The strategy of the immune system for making
antibodies is to create a large repertoire of antibody structures
(di¡ering in the sequences and structures of the loops), and to
select out those with the required antigen binding activities.
The repertoire of antibodies is created during B-cell devel-
opment by DNA rearrangement and combinatorial assembly
of di¡erent genetic segments [3]. The heavy chain variable
genes are assembled from the combination of members of
three di¡erent classes of segments (VH, D and JH); the light
chain variable genes from two classes of segments (VV and JV ;
or VU and JU). Each of the V segments contributes two of the
hypervariable loops. The third loop is contributed by the
junctions of the segments and further sequence diversity is
provided by the D segment (in the case of the heavy chain)
and trimming and addition of nucleotides at the junctions.
Recently the human VH, VU, VV and D segments have been
mapped, cloned and sequenced. We now know that human
antibody heavy chains can be assembled from any of about 51
VH, 25 D, and 6 JH segments, and human light chains from
any of about 31 VV and 4 JV (or 40 VU and 5 JU) segments
(for a compilation, VBASE, see www.mrc-cpe.cam.ac.uk/imt-
doc/public/INTRO.html).
The antibodies encoded by the assembled segments are ex-
pressed on the surface of B-lymphocytes. Each lymphocyte
bears a single antibody but the population of lymphocytes
(about 107 lymphocyte clones in a mouse or more than 109
in a human) constitutes a large repertoire of di¡erent antibody
structures. On binding to antigen a selected lymphocyte is
triggered into di¡erentiation leading to a plasma cell that
secretes soluble complementary antibody into the serum.
The binding a⁄nities of antibodies selected from such a pri-
mary repertoire are modest (WM for the mouse). However the
antigen-selected lymphocytes also di¡erentiate into memory
cells (that continue to display surface antibody), and in this
process the rearranged V genes are subjected to random so-
matic mutation. On further challenge with the same antigen,
memory cells bearing mutant antibodies with improved bind-
ing a⁄nities are selected (by competition for limiting antigen).
In this way the binding a⁄nities can be improved by several
orders of magnitude [4,5].
2. Creating the repertoire
To mimic the strategy of the immune system, we ¢rst need
to create a repertoire of antibody genes. Repertoires can be
created by cloning the natural rearranged human V genes
from peripheral blood lymphocytes [6,7] ; however this article
will focus on the creation of synthetic repertoires directly from
(unrearranged) V gene segments. Thus an entirely synthetic
repertoire of human variable region genes was created by
assembly of each of the human VH segments with D segments
of random nucleotides together with a human J segment [8];
likewise each of the human VV (or VU) segments with a JV (or
JU) segment [9].
Filamentous bacteriophage provides a means of display and
selection of peptides [10,11] and proteins [12,13], and in par-
ticular antibody fragments with binding activities. Thus in the
genes encoding the antibody heavy and light chain variable
domains are linked (as ‘single chain Fv fragments’) [14,15] and
fused to the gene encoding the minor coat protein p3, the
phage encapsidate the antibody genes and display the ‘single
chain Fv fragment’ on the surface [13]. The genes encoding
antibody fragments of prede¢ned binding speci¢city can there-
fore be isolated by binding of the phage to antigen-coated
surfaces. By using several cycles of selection (and growth of
the enriched phage in bacteria between cycles), it is possible to
isolate a single binder from s 109 non-binders. Antibody
fragments can also be assembled as two chain Fab fragments,
by fusion of one chain to the phage and secretion of the other
chain into the bacterial periplasm [16,17]. The ¢lamentous
phage, like the B-cell, provide a vehicle for linking the anti-
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body ‘genotype’ to ‘phenotype’, thereby allowing multiple
cycles of selection.
Synthetic antibody gene repertoires have been cloned into
¢lamentous bacteriophage to create phage repertoires of 107
to s 1010 phage clones [8,9,18]. The selection of such reper-
toires by binding of the phage to a range of di¡erent antigens
has usually led to the isolation of phage with antigen binding
activities. Indeed phage has been isolated that bind to protein
antigens and to haptens, to foreign and self- (human) antigens
and to highly conserved antigens; the binding is highly spe-
ci¢c to the selecting antigen.
Soluble and folded antibody fragments can be produced by
secretion from bacteria [19,20]; by introducing an amber stop
codon between the scFv genes and the p3 protein, the frag-
ments are displayed on phage produced from infected amber
suppressor strains of bacteria, or secreted into the periplasm
of infected non-suppressor strains [16]. Antibody fragments
isolated from synthetic phage repertoires have been used for
immunocytochemistry and for Western blots [18]. However
the binding a⁄nities were only moderate (105^106 M31). Im-
proved binding a⁄nities can be obtained by using larger rep-
ertoires (with greater diversity) [9] or by mutation of selected
clones.
3. Mutation
For the a⁄nity maturation of the synthetic antibodies it is
necessary to introduce mutations, and then to select between
phages displaying antibodies di¡ering only slightly in binding
a⁄nity. Random mutations can be introduced in a variety of
ways; for example by error-prone PCR [21], or by growth of
the phage in a bacterial mutator strain [22]. The rate of mu-
tation in the mutD5 strain is about 1/2000 bp, with transitions
favoured over transversions, much as in somatic mutation in
vivo.
For selection, it is possible to take advantage of di¡ering
dissociation rates of the phage from antigen. If two phages are
bound to a surface that is then washed, the phages with slow-
er dissociation rate are preferentially retained. As the dissoci-
ation rates follow an exponential decay, small di¡erences in
the dissociation rates can, over long wash times, lead to large
enrichment factors [23]. By many cycles of mutation and strin-
gent selection, it was possible to improve the binding a⁄nity
of a human antibody against a hapten by two orders of mag-
nitude [24]. For selection of high a⁄nity interactions it is also
desirable to avoid the e¡ects of multivalent interactions be-
tween the antibody fragments displayed on the phage and the
solid phase antigen. The use of a phagemid to encode the
antibody fused to p3, and a helper phage, favours the display
of less than a single antibody fragment, and thereby is mini-
mising avidity e¡ects in the selection process [25].
In the immune system, mutations are also focussed at ‘hot-
spots’ ; these tend to occur in antigen binding loops, in partic-
ular the ¢rst hypervariable loop of human VH and VU genes.
With synthetic antibodies, mutations have also been focussed
in loops using site directed mutagenesis [27,28] and this has
led to dramatic a⁄nity improvements and antibodies with
nanomolar (and sometimes even picomolar) binding a⁄nities.
Such antibody fragments have been used for tumour imaging
[28].
It therefore appears that by following what we know of the
strategy of the immune system and using many of the same
building blocks it is possible to make synthetic antibodies of
prede¢ned speci¢city and with useful binding a⁄nities.
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Fig. 1. A scheme adapted from [2] to compare the strategy of the natural and synthetic immune system for making antibodies.
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4. Repertoire design
The availability of an arti¢cial immune system opens up
further opportunities to understand the strategy of the im-
mune system and to improve further our approaches to mak-
ing synthetic repertoires.
Perhaps one of the areas of greatest potential is that of
repertoire design. For example, although the immune system
uses many di¡erent V gene segments, the structural diversity is
much more limited, as the segments cluster into families of
related sequences, and utilise loops with a limited number of
folds [29]. Some segments are used preferentially; furthermore
the same folds as represented in these segments also dominate
the repertoire. The reasons for the domination of these seg-
ments and folds are not clear. The creation of synthetic rep-
ertoires based on these single folds may help to identify
whether such repertoires are su⁄cient for recognition of the
complete ‘universe’ of antigens.
A further aspect of repertoire design is the location of se-
quence diversity. By comparing the sequences of rearranged
antibody genes with those of the segment building blocks, it is
possible to compile maps of sequence diversity in the antigen
binding site before and after somatic mutation. The patterns
of diversity are complementary; the greater the diversity in
the primary repertoire, the less the diversity after somatic
mutation (and vice versa) [30]. Presumably the mutation of
a residue in a ‘crude’ binding site that already makes an in-
timate contact with antigen is more likely to destroy the in-
teraction than the mutation of residues directly adjacent. Such
features of ‘complementarity’ could be advantageously incor-
porated into the design of synthetic repertories.
5. Implications for other proteins
The creation of a primary antibody repertoire involves the
assembly of structural elements with a common fold. Presum-
ably other proteins could be engineered in the same way. In-
deed the creation of gene repertoires by extensive recombina-
tion between related proteins appears to be directly analogous
to the creation of the primary antibody repertoire (and indeed
very similar to the generation of antibodies in birds which
appears to use gene conversion) [31,32]. Likewise the evolu-
tion of proteins by mutation and selection is directly analo-
gous to a⁄nity maturation in antibodies [33]. Approaches
that harness all the stratagems of the immune system for
making antibodies would seem to have the potential for creat-
ing and re¢ning proteins with a wealth of new activities.
Acknowledgements: I would like to thank Dr. Ian Tomlinson for dis-
cussions of aspects of repertoire design.
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